Evidence map›Paper›PMID 34996966›Full record

ArticleScientific reports2022

Robust LC3B lipidation analysis by precisely adjusting autophagic flux.

Martina P Liebl, Sarah C Meister, Lisa Frey, Kristina Hendrich, Anja Klemmer, Bettina Wohlfart, Christopher Untucht, Judith Nuber, Christian Pohl, Viktor Lakics

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Frontiers in pharmacology · 2026
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Martina P LieblNeuroscience Discovery, AbbVie Deutschland GmbH & Co KG, Ludwigshafen am Rhein, Germany. martina.morawe@abbvie.com.
Sarah C MeisterClinical Cooperation Unit Translational Radiation Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital (UKHD) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Lisa FreyDepartment of Biotechnology, Mannheim University of Applied Sciences, Mannheim, Germany.
Kristina HendrichMikrogen GmbH, Neuried, Germany.
Anja KlemmerCentre for Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany.
Bettina WohlfartNeuroscience Discovery, AbbVie Deutschland GmbH & Co KG, Ludwigshafen am Rhein, Germany.
Christopher UntuchtNeuroscience Discovery, AbbVie Deutschland GmbH & Co KG, Ludwigshafen am Rhein, Germany.
Judith NuberNeuroscience Discovery, AbbVie Deutschland GmbH & Co KG, Ludwigshafen am Rhein, Germany.
Christian PohlNeuroscience Discovery, AbbVie Deutschland GmbH & Co KG, Ludwigshafen am Rhein, Germany.
Viktor LakicsNeuroscience Discovery, AbbVie Deutschland GmbH & Co KG, Ludwigshafen am Rhein, Germany. viktor.lakics@abbvie.com.
AbbVie (Germany) · DEMannheim University of Applied Sciences · DENational Center for Tumor Diseases · DEUniversity Hospital Heidelberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autophagic flux can be quantified based on the accumulation of lipidated LC3B in the presence of late-stage autophagy inhibitors. This method has been widely applied to identify novel compounds that activate autophagy. Here we scrutinize this approach and show that bafilomycin A1 (BafA) but not chloroquine is suitable for flux quantification due to the stimulating effect of chloroquine on non-canonical LC3B-lipidation. Significant autophagic flux increase by rapamycin could only be observed when combining it with BafA concentrations not affecting basal flux, a condition which created a bottleneck, rather than fully blocking autophagosome-lysosome fusion, concomitant with autophagy stimulation. When rapamycin was combined with saturating concentrations of BafA, no significant further increase of LC3B lipidation could be detected over the levels induced by the late-stage inhibitor. The large assay window obtained by this approach enables an effective discrimination of autophagy activators based on their cellular potency. To demonstrate the validity of this approach, we show that a novel inhibitor of the acetyltransferase EP300 activates autophagy in a mTORC1-dependent manner. We propose that the creation of a sensitized background rather than a full block of autophagosome progression is required to quantitatively capture changes in autophagic flux.

Indexed as

AutophagyLipid MetabolismAutophagosomesBiological AssayBiomarkersChloroquineDose-Response Relationship, DrugE1A-Associated p300 ProteinHeLa CellsHumansMacrolidesMechanistic Target of Rapamycin Complex 1Microtubule-Associated Proteinsbafilomycin A1BiomarkersChloroquineE1A-Associated p300 ProteinEP300 protein, humanMacrolidesMAP1LC3B protein, humanMechanistic Target of Rapamycin Complex 1Microtubule-Associated Proteins

Identifiers

PMID34996966
PMCPMC8742033
OpenAlexW4205692549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.